Skip to ContentSkip to Navigation
About us Latest news News News articles

Development and evaluation of PET tracers for imaging B-glucuronidase activity in cancer and inflammation

25 January 2012

Ph ceremony: Ms. I. Farinha Antunes, 14.30 uur, Aula Academiegebouw, Broerstraat 5, Groningen

Disseration: Development and evaluation of PET tracers for imaging B-glucuronidase activity in cancer and inflammation

Promotor(s): prof. R.A.J.O.Dierckx, prof. H.G. Haisma, prof. P.H. Elsinga

Faculty: Medical Sciences

The ideal treatment should cure a disease without harming healthy tissues. Therefore, a new treatment strategy for cancer and certain inflammatory diseases has been developed called Prodrug therapy. In this approach, a toxic drug is “disguised” as a non-toxic compound called prodrug, which can be reactivated by an enzyme at the target site, releasing the drug only where it is needed. β-Glucuronidase is being explored as an enzyme to activate prodrugs. Not every patient possesses the same amount of β-glucuronidase at the target site. PET imaging of β-glucuronidase activity could allow monitoring β-glucuronidase activity over time. Provided that a suitable tracer is available, PET might give information about the levels of β-glucuronidase present in various tissues in a patient. Thus, PET might be used to predict which patients would benefit from β-glucuronidase prodrug therapy.

The aim of this project was to develop a PET tracer for imaging β-glucuronidase activity and to use it for evaluation of β-glucuronidase in animal models for various disorders. Our in vivo studies show that the PET tracer [18F]FEAnGA can detect and quantify extracellular β-glucuronidase activity in tumors, in sterile inflammatory lesions and in brain infection. We were also able to demonstrate with [18F]FEAnGA PET that a single dose of cytostatic drug can increase β-glucuronidase activity in tumors. This study may open the way to a two-step chemotherapy-prodrug approach, in which tumors are treated with a single dose of a cytostatic drug to increase the levels of β-glucuronidase prior the prodrug treatment.

Last modified:13 March 2020 12.59 a.m.
View this page in: Nederlands

More news

  • 29 November 2023

    UMCG opent nieuwe faciliteit voor microbioomonderzoek 

    Vandaag opent het UMCG de Groningen Microbioom Hub: een nieuwe faciliteit met state-of-the-art technologie waarin alle UMCG-expertise op het gebied van microbioomonderzoek samenkomt. Dit zorgt voor unieke mogelijkheden in onderzoek en maakt nieuwe...

  • 28 November 2023

    Science: more exciting than showbiz

    Science often seems very complicated. Most people probably don't really know what researchers do, and what it takes to make a breakthrough. That is why it is important to keep the general public informed of what is happening in science, says Iris...

  • 13 November 2023

    UMCG beantwoordt vragen patiënten met hulp van AI

    Het UMCG zet kunstmatige intelligentie (artificial intelligence, afgekort AI) in om zorgverleners te helpen bij het beantwoorden van schriftelijke vragen van patiënten. Dit gebeurt in samenwerking met andere ziekenhuizen vanuit de EPIC Nederlandse...